Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137258

Published: 2020

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Joo Y. Song, MD, Caoimhe Egan, Alyssa Bouska, PhD, Weiwei Zhang, PhD, Qiang Gong, Girish Venkataraman, MD MBBS, Alex F. Herrera, MD, Lu Chen, PhD, Rebecca Ottesen, Joyce Niland, PhD, Victoria Bedell, Maria Valle-Catuna, Joyce Murata-Collins, PhD, Dennis D. Weisenburger, MD, Javeed Iqbal, PhD, Elaine S. Jaffe, MD, Wing C. Chan, MD

Blood (2019) 134 (Supplement_1): 1486.

https://doi.org/10.1182/blood-2019-125095

Published: 2019

Journal Articles

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, NI-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 4623.

https://doi.org/10.1182/blood-2019-131357

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Sirin Khajavian, MD, Matthew Lewis Chase, Justin Darrah, MD, David G. Maloney, MD PhD, Vincent T. Ho, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Stephen J Forman, Auayporn P. Nademanee, MDBS, Yi-Bin Chen, MD, Philippe Armand, MD PhD, Mazyar Shadman, MD MPH

Blood (2018) 132 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2018-99-114155

Published: 2018

Journal Articles

New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Blood (2018) 132 (Supplement 1): 346.

https://doi.org/10.1182/blood-2018-99-117636

Published: 2018

Journal Articles

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Lu Chen, PhD, Alex F. Herrera, MD, Matthew Mei, MD, Katrina McBride, Rosie Abary, Tanya Siddiqi, MD, Leslie Popplewell, MD, Stephen J Forman, Steven T Rosen, Larry W Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2018-99-110403

Published: 2018

Journal Articles

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Blood (2015) 126 (23): 2636.

https://doi.org/10.1182/blood.V126.23.2636.2636

Published: 2015

Journal Articles

Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group

Kara M. Kelly, MD, Peter D. Cole, MD, Lu Chen, PhD, Kenneth B Roberts, MD, David C. Hodgson, MD, Kathleen McCarten, MD, Steve Y Cho, MD, Cindy Schwartz, MD

Blood (2015) 126 (23): 3927.

https://doi.org/10.1182/blood.V126.23.3927.3927

Published: 2015

Journal Articles

18 f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG) AHOD0031

Steve Y Cho, MD, Kathleen M McCarten, MD, Lu Chen, PhD, Debra L Friedman, MD, MS, Suzanne L Wolden, MD, Kathryn Karolczuk, Cindy L Schwartz, MD, MPH, Kara M Kelly, MD

Blood (2012) 120 (21): 1530.

https://doi.org/10.1182/blood.V120.21.1530.1530

Published: 2012

Journal Articles

Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group

Angela Punnett, MD, Stephanie Terezakis, MD, Lu Chen, PhD, Allen Buxton, MSc, Suzanne L Wolden, MD, Burton Appel, MD

Blood (2012) 120 (21): 3659.

https://doi.org/10.1182/blood.V120.21.3659.3659

Published: 2012

Journal Articles

The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma,

Cindy Schwartz, MD, MPH, Lu Chen, PhD, Louis Constine, MD, Suzanne Wolden, Frank G Keller, MD, Kara M Kelly, MD, Debra l Friedman, MD, MS

Blood (2011) 118 (21): 3649.

https://doi.org/10.1182/blood.V118.21.3649.3649

Published: 2011

Journal Articles

Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children's Oncology Group

Karen S. Fernández, MD, Lu Chen, PhD, Cindy Schwartz, MD, MPH, Allen R. Chauvenet, MD, PhD, Pedro A. de Alarcón, MD

Blood (2011) 118 (21): 91.

https://doi.org/10.1182/blood.V118.21.91.91

Published: 2011

Journal Articles

Coordinate Regulation of NF-κB Subunit Expression In Pediatric Hodgkin Lymphoma Patients with Rapid Early Response to Therapy, but Not Slow Early Response to Therapy

Terzah M Horton, MD/PhD, Andrea Sheehan, MD, Dolores Lopez-Terrada, MD, Robert Hutchison, MD, Sonya Narendra, MD, Meng-Fen Wu, PhD, Lu Chen, PhD, Hao Liu, PhD

Blood (2010) 116 (21): 2680.

https://doi.org/10.1182/blood.V116.21.2680.2680

Published: 2010

Journal Articles

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

Debra l Friedman, MD, MS, Suzanne Wolden, Louis Constine, MD, Lu Chen, PhD, Kathleen M McCarten, MD, T. J Fitzgerald, Pedro De Alarcon, MD, Allen R. Chen, MD, PhD, MHS, Robert Hutchison, MD, Peter Ehrlich, Nathan L. Kobrinsky, MD, FRCP, Meghan Higman, Shirley Hogan, Lorna Roll, Tanya Trippett, Cindy Schwartz, MD

Blood (2010) 116 (21): 766.

https://doi.org/10.1182/blood.V116.21.766.766

Published: 2010

Journal Articles

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Frank G Keller, MD, James Nachman, MD, Louis Constine, MD, John Thomson, MD, Kathleen M McCarten, MD, Lu Chen, PhD, Cindy Schwartz, MD

Blood (2010) 116 (21): 767.

https://doi.org/10.1182/blood.V116.21.767.767

Published: 2010

Journal Articles

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allen R. Chen, MD, PhD, MHS, Robert Hutchison, MD, Allan Hess, PhD, Sharon Gardner, MD, Tanya Trippett, MD, Pedro de Alarcon, MD, Shirley Hogan, PharmD, Joy Mitchell, CRA, Vickie Massey, MD, Louis S. Constine, MD, Lu Chen, PhD, Cindy L. Schwartz, MD

Blood (2007) 110 (11): 1896.

https://doi.org/10.1182/blood.V110.11.1896.1896

Published: 2007

NARROW

Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group

18 f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG) AHOD0031

Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group

The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma,

Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children's Oncology Group

Coordinate Regulation of NF-κB Subunit Expression In Pediatric Hodgkin Lymphoma Patients with Rapid Early Response to Therapy, but Not Slow Early Response to Therapy

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only